A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00001003 |
|
Recruitment Status :
Completed
First Posted : August 31, 2001
Last Update Posted : November 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count < 200 cells/mm3. To establish the range of pentamidine (PEN) deposition in AIDS patients participating in ACTG 021 and ACTG 081. To identify factors (breathing pattern, pulmonary function) that may be important in affecting the actual dose delivered to a given patient.
The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pneumonia, Pneumocystis Carinii HIV Infections | Drug: Pentamidine isethionate Drug: Zidovudine | Not Applicable |
The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer.
Approximately 4 weeks after patients in ACTG 021 and ACTG 081 have begun PEN aerosol therapy for the prevention of PCP, patients undergo the first radioactive aerosol study. The patient inhales a mist while sitting with his/her back against a gamma camera. The resulting picture outlines the lungs. This mist contains a single dose of PEN mixed with a small amount of radioactivity (99m-technetium ertechnetate). The gamma camera determines where the particles deposit in the lungs. The radioactivity exposure is equivalent to a typical xray of the ribs. This procedure takes about 45 minutes; 6 hours later another 30-minute gamma camera image is obtained. Blood is withdrawn to measure the blood level of PEN as done in ACTG 021 and ACTG 081. The entire procedure is repeated near the end of the prophylactic schedule (about 10-12 months after the start of aerosol PEN treatments).
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 20 participants |
| Primary Purpose: | Treatment |
| Official Title: | Aerosols in the Treatment of Pneumocystis Carinii Pneumonia: A Nested Study Quantitating the Delivery of Aerosolized Pentamidine for Prophylaxis of PCP in Protocols ACTG 021 and ACTG 081 |
| Actual Study Completion Date : | January 1992 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Treatment:
Allowed:
- Local radiation for Kaposi's sarcoma.
Patients who successfully completed a course of study therapy for acute Pneumocystis carinii pneumonia (PCP) and who met the inclusion criteria for Protocol ACTG 021 or ACTG 081 and were randomized to the aerosolized pentamidine arm.
- Patients who are currently receiving aerosolized pentamidine as prophylactic therapy for PCP.
Exclusion Criteria
The following patients are excluded:
- Those enrolled in ACTG 021 and randomized to the oral prophylaxis arm.
- Those enrolled in ACTG 081 and randomized to the trimethoprim / sulfamethoxazole and dapsone arms.
Prior Treatment:
Excluded within 2 weeks of study entry:
- Transfusions of blood or red blood cells.
Co-Existing Condition:
- Significant adverse effects.
Active substance abuse.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001003
| United States, New York | |
| SUNY - Stony Brook | |
| Stony Brook, New York, United States, 11794 | |
| Study Chair: | GC Smaldone |
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00001003 |
| Other Study ID Numbers: |
ACTG 079 11054 ( Registry Identifier: DAIDS ES Registry Number ) |
| First Posted: | August 31, 2001 Key Record Dates |
| Last Update Posted: | November 4, 2021 |
| Last Verified: | October 2021 |
|
AIDS-Related Opportunistic Infections Pneumonia, Pneumocystis carinii Pentamidine Nebulizers and Vaporizers |
Lung Administration, Inhalation Acquired Immunodeficiency Syndrome Zidovudine |
|
Pneumonia Pneumonia, Pneumocystis Infections Respiratory Tract Infections Lung Diseases Respiratory Tract Diseases Lung Diseases, Fungal Mycoses Bacterial Infections and Mycoses Pneumocystis Infections Zidovudine Pentamidine Antimetabolites |
Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Antiviral Agents Anti-Infective Agents Anti-HIV Agents Anti-Retroviral Agents Antifungal Agents Antiprotozoal Agents Antiparasitic Agents Trypanocidal Agents |